Patents Issued in February 18, 2016
-
Publication number: 20160046655Abstract: The present invention relates to a novel process for preparing ceftaroline fosamil as well as to intermediates of this process.Type: ApplicationFiled: September 27, 2013Publication date: February 18, 2016Inventors: Hubert Sturm, Josef Wieser
-
Publication number: 20160046656Abstract: The present invention provides: O-cyclic phytospingosine-1-phosphate (0-C-P1P), N-cyclic phytospingosine-1-phosphate (N-C-P1P), a pharmaceutically acceptable salt thereof, or a solvate thereof; a preparation method therefor; a cosmetic composition comprising the same for preventing hair loss or for growing hair; and a pharmaceutical composition for preventing and treating hair loss or for growing hair.Type: ApplicationFiled: April 4, 2013Publication date: February 18, 2016Applicant: PHYTOS CO., LTD.Inventor: Myeong Jun CHOI
-
Publication number: 20160046657Abstract: A series of bicycloalkene-palladium compounds having utility as addition polymerization catalysts are disclosed. Also disclosed are the methods of making these compounds.Type: ApplicationFiled: August 17, 2015Publication date: February 18, 2016Inventor: ANDREW BELL
-
Publication number: 20160046658Abstract: The present invention relates to a process for the preparation of a compound of formula (I), wherein X is —CH2—, —CH2—CH2—, —CH2—CH2—CH2— or —CH2—CH2—CH2—CH2—; Y1 is —CH2—; —CH2—CH2— or —NH—; Y2 is NHR7, or SH; wherein R7 is hydrogen, C1-C4alkyl or phenyl; R—1 and R2, independently from each other, represent aliphatic or aromatic groups; R3 and R4, independently from each other, represent aliphatic or aromatic groups; R5 and R6 are each hydrogen or represent together with the carbon atoms to which they are bonded, a phenyl ring; which process comprises reacting a compound of formula II [RuCI2(R8)n]m (II), wherein n is 1 and m is >1 which represents a polymeric structure if R8 is a molecule containing two alkene or alkyne moieties coordinating in an hapto-2 coordination mode to the metal; or n is 4 and m is 1 if R8 is a nitrogen, oxygen or sulfur containing molecule in which said nitrogen, oxygen or sulfur coordinate to the metal; in the presence of an inert solvent which boiling point is from 112° C.Type: ApplicationFiled: April 1, 2014Publication date: February 18, 2016Applicant: SYNGENTA PARTICIPATIONS AGInventors: Christian LOTHSCHUETZ, Alexandre Christian SAINT-DIZIER
-
Publication number: 20160046659Abstract: The invention relates to a device (1) for purifying nucleic acids composed of a one-piece hollow body (2) comprising an upper portion (3) having an inlet port (5) and a lower portion (4) having an outlet port (6), wherein within the hollow body (2) at the least one nucleic acid-binding matrix (7) is arranged, wherein the device (1) is characterized in that between the upper portion (3) and the lower portion (4) a predetermined breaking point (10) is provided and the nucleic acid-binding matrix (7) is arranged in the lower portion (4). The invention further relates to a method for producing such a device, a method for purifying nucleic acids by means of a device according to the invention, and a kit comprising a device according to the invention.Type: ApplicationFiled: August 10, 2015Publication date: February 18, 2016Inventors: Hubert Greiler, Markus Meusel
-
Publication number: 20160046660Abstract: The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain.Type: ApplicationFiled: March 15, 2014Publication date: February 18, 2016Inventor: David Eugene PEREIRA
-
Publication number: 20160046661Abstract: Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael Gray, Sang Min Lim, Hwan Geun Choi, Kenneth Dale Westover
-
Publication number: 20160046662Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
-
Publication number: 20160046663Abstract: A method of forming a cross-linked protein structures includes preparing a solution of protein dissolved in a benign solvent and forming an intermediate protein structure from the solution. The intermediate protein structure can be cross-linked by providing for a specific ratio of chemical cross-linking agents to form the cross-linked protein structure. The solution can be prepared by adding a cross-linker of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) at a ratio of two-to-one of NHS to EDC to alcohol. PBS buffer (20×) can be added to the solution until the volume ratio of PBS buffer (20×) to alcohol is about one-to-one. About 16 percent by weight of protein can be dissolved in the solution. The solution can be electrospun to form an intermediate protein structure. After a period of time, the protein structure can be cross-linked to form the cross-linked protein structure.Type: ApplicationFiled: May 22, 2015Publication date: February 18, 2016Inventors: Gary E. Wnek, Lenghui Meng
-
Publication number: 20160046664Abstract: The present invention relates to the purification of target molecules like immunoglobulins from plasma. The use of a certain type of ion exchanger based on a crosslinked polyvinylether results in especially high yields of the target molecule.Type: ApplicationFiled: August 10, 2015Publication date: February 18, 2016Applicant: MERCK PATENT GMBHInventors: Annika ALDINGER, Achim SCHWAEMMLE, Matthias JOEHNCK, Dirk MUELLER, Marc MAZUR
-
Publication number: 20160046665Abstract: This invention discloses a peptide ligand with antibody selectivity and the application thereof. The peptide ligand with antibody selectivity comprises peptide ligand consisted of a sequence with 4 to 6 amino acids. The peptide ligand with antibody selectivity is able to bind with the hydrophobic region at the bottom of antibody's Fc region through non-covalent bonding. The mentioned peptide ligand with antibody selectivity can be applied to biochip for antibody oriented immobilization, and the biochip can provide high recognition efficiency to antigen. Besides, the mentioned peptide ligand with antibody selectivity can be applied as antibody purification material for purifying antibody with respective peptide ligand with antibody selectivity.Type: ApplicationFiled: February 17, 2015Publication date: February 18, 2016Inventors: Ruoh-Chyu Ruaan, Ching-Wei Tsai, Siang-Long Jheng, Wei-Chih Tseng, Wen-Yih Chen
-
Publication number: 20160046666Abstract: Methods for the synthesis and use of functionalized, substituted naphthalenes are described. The functionalized, substituted naphthalenes display useful properties including liquid crystals and fluorescence properties, such as solvatochromatic fluorescence, with high quantum yields, Stoke's shift, and show emission maxima that are significantly red-shifted.Type: ApplicationFiled: September 14, 2015Publication date: February 18, 2016Inventor: Kay M. Brummond
-
Publication number: 20160046667Abstract: Crystalline forms of anamorelin which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.Type: ApplicationFiled: October 30, 2015Publication date: February 18, 2016Inventors: Keith Lorimer, Seemon H. Pines, Bernhard Paul, Benjamin Littler
-
Publication number: 20160046668Abstract: Provided are peptides, fusion proteins which include the peptide sequences, compositions comprising such peptides and fusion proteins, and methods for making and using the compositions. The peptides are characterized as being able to selectively bind to components of the endothelial compartment that are exposed during the period between 1 and 7 days after androgen deprivation.Type: ApplicationFiled: March 14, 2014Publication date: February 18, 2016Applicant: HEALTH RESEARCH, INC.Inventors: Gary SMITH, Ryan WILLARD
-
Publication number: 20160046669Abstract: A method is provided for inhibiting proliferation of a high LIX1L-expressing tumor cell, in which the expression or function of a LIX1L gene with respect to a tumor cell highly expressing the LIX1L gene is inhibited.Type: ApplicationFiled: April 2, 2014Publication date: February 18, 2016Inventors: SATOKI NAKAMURA, HARUHIKO SUGIMURA
-
Publication number: 20160046670Abstract: There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a ?-sheet tape-like substructure.Type: ApplicationFiled: October 20, 2015Publication date: February 18, 2016Applicant: University of LeedsInventors: Neville Boden, Amalia Aggeli, Eileen Ingham, Jennifer Kirkham
-
Publication number: 20160046671Abstract: Provided herein are polypeptides containing stabilized therapeutic peptides related to KRAS guanidine exchange factor (SOS1). Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that includes administering to a subject one of the polypeptides. This disclosure relates to structurally stabilized therapeutic peptides related to KRAS guanidine exchange factor (SOS1), and methods of using such peptides in the treatment of cancer.Type: ApplicationFiled: March 14, 2014Publication date: February 18, 2016Inventors: Elizaveta LESHCHINER, Loren D. WALENSKY
-
Publication number: 20160046672Abstract: The present invention relates to cross-linked peptides that are associated with human eIF4G and bind to eIF4E, uses thereof and pharmaceutical compositions comprising the peptides.Type: ApplicationFiled: February 28, 2014Publication date: February 18, 2016Inventors: Christopher John Brown, David Philip Lane, Soo Tng Quah, Dilraj Lama, Chandra Shekhar Verma
-
Publication number: 20160046673Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.Type: ApplicationFiled: April 11, 2014Publication date: February 18, 2016Applicant: BICYCLE THERAPEUTICS LIMITEDInventors: Daniel Paul Teufel, Catherine Stace, Edward Walker, John Tite
-
Publication number: 20160046674Abstract: Provided herein are inventive enopeptin compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Brown UniversityInventor: Jason K. Sello
-
Publication number: 20160046675Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Applicant: The USA, as represented by the Secretary, Departm- ent of Health and Human ServiceInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Publication number: 20160046676Abstract: The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.Type: ApplicationFiled: April 10, 2014Publication date: February 18, 2016Inventor: TAKANORI SATO
-
Publication number: 20160046677Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: ApplicationFiled: October 30, 2015Publication date: February 18, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Ira H. Pastan, Masanori Onda, Wenhai Liu
-
Publication number: 20160046678Abstract: Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.Type: ApplicationFiled: March 14, 2014Publication date: February 18, 2016Inventors: Viktor ROSCHKE, David LAFLEUR, David M. HILBERT, Peter KIENER
-
Publication number: 20160046679Abstract: The present disclosure provides certain silk-fibroin compositions with particular characteristics and/or properties. In some embodiments, the disclosure provides low molecular weight compositions. In some embodiments, the disclosure provides silk fibroin compositions that comprise an active (e.g., a biological) agent or component. In some embodiments, the disclosure provides low molecular weight silk fibroin compositions that comprise an active (e.g., a biological) agent or component. In some embodiments, an active agent is stabilized in a silk composition, e.g., for a period of time and/or against certain conditions or events. In some embodiments, a component present in a silk fibroin composition may be subject to analysis and/or characterization. In some embodiments, a component present in a silk fibroin composition may be recovered from the composition.Type: ApplicationFiled: March 14, 2014Publication date: February 18, 2016Applicant: Trustees of Tufts CollegeInventors: Jonathan A. Kluge, Fiorenzo G. Omenetto, David L. Kaplan
-
Publication number: 20160046680Abstract: This document provides methods and materials involved in radiotracer imaging using NIS polypeptides. For example, methods and materials for performing imaging techniques that increase the detection sensitivity and resolution of radiotracers localized by NIS reporter gene expression and/or decrease background signals that can be attributed to endogenously expressed NIS polypeptides are provided.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Inventors: Stephen James Russell, Kah-Whye Peng, Patrycja Lech
-
Publication number: 20160046681Abstract: The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a promoter region of a nuclear receptor genefused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these promoter regions of a nuclear receptor gene regulate the expression of the glucocorticoid receptor, the androgen receptor, or the estrogen receptor ESR1. Artificial transcription factors directed against the glucocorticoid receptor are useful in the treatment of diseases modulated by glucocorticoids, such as inflammatory processes, diabetes, obesity, coronary artery disease, asthma, celiac disease and lupus erythematosus.Type: ApplicationFiled: April 2, 2014Publication date: February 18, 2016Applicant: ALIOPHTHA AGInventors: Albert NEUTZNER, Josef FLAMMER, Alice HUXLEY
-
Publication number: 20160046682Abstract: The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a gene promoter, engineered to overcome endosomal entrapment after transduction into cells. Such artificial transcription factor comprises a polydactyl zinc finger protein fused to an inhibitory or activatory protein domain, a nuclear localization sequence, a protein transduction domain, and an endosome-specific protease-recognition site. These transducible artificial transcription factors are particularly useful for the treatment of diseases caused or modulated by membrane-bound receptor proteins, nuclear receptor proteins or products of haploinsufficient genes.Type: ApplicationFiled: April 2, 2014Publication date: February 18, 2016Applicant: ALIOPHTHA AGInventors: Albert NEUTZNER, Josef FLAMMER, Alice HUXLEY
-
Publication number: 20160046683Abstract: Disclosed herein are methods and compositions for correction and/or mutation of genes associated with Parkinson's Disease as well as clones and animals derived therefrom.Type: ApplicationFiled: October 29, 2015Publication date: February 18, 2016Inventors: Rudolf Jaenisch, Josee Laganiere, Frank Soldner, Lei Zhang
-
Publication number: 20160046684Abstract: Cancer, obesity, and diabetes are examples of PTP1B-related diseases. The invention herein provides embodiments of therapeutic methods and compositions for treating PTP1B related diseases by engineering peptides that bind to the functional spine of PTP1B to alter the conformation of the protein and inhibit a function of PTP1B. Molecules bind to amino acid residues of the functional spine of PTP1B, regulate the catalytic cycle, and treat PTP1B-related diseases. For example, molecules bind to at least one of Tyr152, Tyr153, His175, Thr178, Pro185, Phe191, Leu192, Asn193, Cys215, Gly218, Phe280, Val287, Trp291, Lys292, Leu294, Ser295, and Glu297 to reduce at least one symptom of a PTP1B related disease.Type: ApplicationFiled: August 14, 2015Publication date: February 18, 2016Applicant: BROWN UNIVERSITYInventors: Wolfgang Peti, Rebecca Page
-
Publication number: 20160046685Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.Type: ApplicationFiled: March 14, 2014Publication date: February 18, 2016Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
-
Publication number: 20160046686Abstract: The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity.Type: ApplicationFiled: August 19, 2015Publication date: February 18, 2016Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Lloyd A. Greene, James Angelastro
-
Publication number: 20160046687Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.Type: ApplicationFiled: October 23, 2013Publication date: February 18, 2016Inventors: Jacques Galipeau, Jiusheng Deng
-
Publication number: 20160046688Abstract: Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (?-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the ?-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.Type: ApplicationFiled: August 19, 2015Publication date: February 18, 2016Applicant: GENZYME CORPORATIONInventors: Michael A. PERRICONE, John Lyle DZURIS, Timothy E. WEEDEN, James E. STEFANO, Clark Q. PAN, Andrea E. EDLING
-
Publication number: 20160046689Abstract: MICA and MICB are expressed on the surface of stressed, virus infected and cancer cells; they bind to their common receptor NKG2D on immune effector cells such as natural killer (NK) cells and some T cells to signal immune responses, including cytotoxicity, towards cells expressing surface MICA or MICB. To evade this immune-surveillance, virus infected cells and cancer cells shed the extracellular domain of their MICA and MICB as soluble forms (sMICA and sMICB) which act as decoys by binding and down-regulating expression of NKG2D on the immune effector cells. Antibodies are provided that specifically bind the soluble forms of both MICA and MICB to inhibit their adverse effects, but do not bind cell- or membrane-bound MICA and MICB to preserve their beneficial immune effects.Type: ApplicationFiled: March 15, 2014Publication date: February 18, 2016Inventor: IAN Wayne CHENEY
-
Publication number: 20160046690Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subject having an anemia and subjects have an ineffective erythropoiesis disorder.Type: ApplicationFiled: March 20, 2015Publication date: February 18, 2016Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
-
Publication number: 20160046691Abstract: The present invention relates to a novel epitope to convert T cell to type 2 helper T (TH2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (SEQ ID No.2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody.Type: ApplicationFiled: June 15, 2015Publication date: February 18, 2016Inventor: Byoung Se Kwon
-
Publication number: 20160046692Abstract: The present invention relates to a method for purifying triple-helical or collagen-like proteins recombinantly produced from a bacterial, yeast or plant host cell.Type: ApplicationFiled: March 21, 2014Publication date: February 18, 2016Inventors: John Alan Maurice Ramshaw, Jerome Anthony Werkmeister, Yong Yi Peng
-
Publication number: 20160046693Abstract: The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an Fc?R-binding domain having Fc? RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule.Type: ApplicationFiled: February 22, 2013Publication date: February 18, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Atsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, Hitoshi Katada, Shojiro Kadono, Futa Mimoto
-
Publication number: 20160046694Abstract: Methods and constructs for expressing biologically active proteins in eukaryotic cells are disclosed. A method for producing a non-conventional expression vector for production of biologically active compounds comprising a primary transcriptional unit and one or more secondary transcriptional units, a primary transcriptional unit encoding promoter, synthetic intron, selectable marker gene and polyadenylation signal or transcriptional terminator and a second transcriptional unit encoding promoter and polypeptide of interest surrounded by insulator sequences and placed in the intron of primary transcriptional unit. The synthetic intron disclosed is positioned at the 5? end of the coding sequence and the synthetic intron capable for accommodating secondary transcriptional unit with base pairs ranging from 500 to 6000 and more.Type: ApplicationFiled: March 28, 2014Publication date: February 18, 2016Inventors: Raj Kumar KUNAPARAJU, Bindu KODATI, Radhika NADIMPALLI
-
Publication number: 20160046695Abstract: The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Inventor: John A. McIntyre
-
Publication number: 20160046696Abstract: The present invention provides murine monoclonal antibody molecules that bind to Merkel cell carcinoma (MCV) polypeptides.Type: ApplicationFiled: August 10, 2015Publication date: February 18, 2016Inventors: Patrick S. Moore, Yuan Chang, Huichen Feng
-
Publication number: 20160046697Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.Type: ApplicationFiled: October 23, 2015Publication date: February 18, 2016Inventors: Luke Robinson, Zachary Shriver, James Myette, Gregory Babcock, Karthik Viswanathan
-
Publication number: 20160046698Abstract: Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing Hla to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a Hla with reduced toxicity, represented by a recombinant mutant form of Hla (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.Type: ApplicationFiled: September 1, 2015Publication date: February 18, 2016Applicant: THE UNIVERSITY OF CHICAGOInventors: Juliane Bubeck-Wardenburg, Olaf Schneewind
-
Publication number: 20160046699Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.Type: ApplicationFiled: April 10, 2014Publication date: February 18, 2016Applicants: KING'S COLLEGE LONDON, LEIBNIZ INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V.Inventors: Julian NAGLIK, David MOYES, Shirley TANG, Bernhard HUBE, Duncan WILSON, Sarah HOFS, Jonathan RICHARDSON
-
Publication number: 20160046700Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides. The technology further relates in part to therapeutic methods for inducing an immune response and treating tumors in a patient.Type: ApplicationFiled: February 13, 2015Publication date: February 18, 2016Inventors: Aaron Edward Foster, David Spencer, Matthew Robert Collinson-Pautz, Kevin Slawin
-
Publication number: 20160046701Abstract: The present invention is based, in part, on our discovery that targeting epitopes within one or more of the EC2-EC5 subdomains of E-cadherin results in the death of epithelial-derived tumor cells but not in the death of normal, healthy epithelial cells or non-epithelial cells including endothelial cells and fibroblasts. Accordingly, the compositions of the invention include polypeptides having an amino acid sequence of one or more of the EC2-EC5 subdomains of E-cadherin and biologically active variants thereof; expression vectors and cells for expressing such polypeptides; and agents (e.g., antibodies) that target the EC2-EC5 subdomains.Type: ApplicationFiled: March 30, 2015Publication date: February 18, 2016Inventors: Sabine M. Brouxhon, M. Kerry O'Banion, Stephanos Kyrkanides
-
Publication number: 20160046702Abstract: The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.Type: ApplicationFiled: July 31, 2015Publication date: February 18, 2016Inventors: Leif Håkansson, Birgitta Clinchy
-
Publication number: 20160046703Abstract: The present invention relates to a novel antigen-binding protein construct or “modubody”, which contains at least three functional single domain modules of an antibody. The modubodies contain a domain from the heavy chain variable region of an antibody (VH), a domain from the light chain variable region of an antibody (VL) and bind monospecifically to an antigen. The modubodies further contain a domain from the constant region of antibodies. The modubodies can be used for diagnostic or therapeutic purposes.Type: ApplicationFiled: September 9, 2015Publication date: February 18, 2016Applicant: ORGENTEC DIAGNOSTIKA GmbHInventor: Robert POPPE
-
Publication number: 20160046704Abstract: A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-?2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity. In addition, uses of the material for developing diagnostic agents and for identifying inhibitors of lipolytic activity for therapeutic purposes are disclosed.Type: ApplicationFiled: October 26, 2015Publication date: February 18, 2016Inventors: Michael J. Tisdale, Penio T. Totorov